23 June 2014 : Original article
Incidence of malignant neoplasia after heart transplantation – a comparison between cyclosporine a and tacrolimus
Uwe FuchsABD, Sarah KleinBCD, Armin ZittermannBCDE, Stephan M. EnsmingerDE, Uwe SchulzADF, Jan F. GummertBDDOI: 10.12659/AOT.890199
Ann Transplant 2014; 19:300-304
Abstract
BACKGROUND: Heart transplant recipients are at increased risk of developing malignant neoplasms. Administration of the calcineurin inhibitors cyclosporine A (CSA) or tacrolimus (TAC) may contribute to this risk.
MATERIAL AND METHODS: We compared tumor incidence in heart transplant recipients receiving either CSA (n=25) or TAC (n=120) as maintenance immunosuppressive therapy. Exclusion criteria were therapy with mammalian target of rapamycin-inhibitors, death within the first postoperative year, re-transplantation, and age less than 18 years.
RESULTS: The 2 study groups were comparable with respect to sex, primary and concomitant diagnoses, and mean follow-up (60.7±19.3 months in the CSA group vs. 59.8±18.1 months in the TAC group; P=0.81). The CSA group was, however, significantly older compared with the TAC group (58.8±11.4 years vs. 49.1±13.0 years, P=0.001), as was the donor age of the CSA group (43.2±11.2 years vs. 37.0±11.7 years, P=0.02). In the CSA group, 5 patients (20%) developed malignant neoplasms compared with 10 patients (8.3%) in the TAC group (P=0.14). Covariate-adjusted 5-year tumor-free survival was comparable between groups (relative risk for the CSA group =1.162 [95% CI: 0.378–3.572; P=0.794]). Moreover, covariate-adjusted 5-year overall survival did not differ between the 2 groups (relative risk for the CSA group =1.95 [95% CI: 0.53–7.19; P=0.36). The incidence of infection, acute rejection, graft vasculopathy, renal failure, and neurological complications was also comparable between the 2 groups.
CONCLUSIONS: Our data indicate that tumor incidence does not significantly differ in patients receiving CSA or TAC as maintenance therapy.
Keywords: Neoplasms, Second Primary, Tacrolimus, Cyclosporine A, Immunosuppression, calcineurin-inhibitors, Heart Transplantation
839 12
In Press
14 Sep 2023 : Case report
Intrahepatic Venous Collateral Circulation and Reverse Blood Flow After Main Hepatic Vein Obstruction: A Ca...Ann Transplant In Press; DOI: 10.12659/AOT.941521
12 Sep 2023 : Original article
Three-Dimensional Printing of Polycaprolactone/Nano-Hydroxyapatite Composite Scaffolds with a Pore Size of ...Ann Transplant In Press; DOI: 10.12659/AOT.940365
04 Sep 2023 : Original article
Analysis of Anxiety and Influencing Factors in Kidney Transplant Recipients and General Public During the C...Ann Transplant In Press; DOI: 10.12659/AOT.941489
04 Sep 2023 : Original article
Prolonged Tracheal Intubation in the ICU as a Possible Risk Factor for Arytenoid Dislocation After Liver Tr...Ann Transplant In Press; DOI: 10.12659/AOT.940727
Most Viewed Current Articles
24 Aug 2021 : Review article
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860